Vitae earns $14M milestone payment from Boehringer Ingelheim
Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance ...
Tags: Boehringer Ingelheim, Company Today Announced That, Diabetes, Discovery, Diseases, Hsd, Hydroxysteroid Dehydrogenase, Metabolic Syndrome, Milestone Payment, Pharmaceutical Companies, Pharmaceuticals Inc, Strategic Alliance, Today Announced That, Treatment Of Diabetes, Vitae Pharmaceuticals